Menu UF Health Home Menu
 

TrialNet ATG-GCSF New Onset Study

Study Name: Effects of Low Dose ATG (Thymoglobulin®) Used Alone or in Combination with GCSF (Neulasta®) in New Onset Diabetes

Principal Investigator: Michael Haller, M.D. 352-273-9264

Coordinator: Miriam Cintron  352-273-5580

or Main Number 352-294-5760

Email: hallemj@peds.ufl.edu or cintrm@peds.ufl.edu

What is the ATG-GCSF Study?

TrialNet researchers at UF are testing whether low dose ATG used alone or in combination with GCSF will help people newly diagnosed with type 1 diabetes to continue to make some of their own insulin.

In the study, TrialNet will compare the progression of diabetes in three groups of people:

  • One group will get infusions of low dose ATG and injections of GCSF.
  • Another group will get infusions of low dose ATG and injections of placebo (a substance that looks like the study drug but contains no active drug).
  • A third group will get placebo infusions and placebo injections (substances that look like the study drugs, but contain no active drugs).

Who can be in the ATG-GCSF Study?

You can be screened for the ATG-GCSF study if:

  • You are 12 to 45 years old,

AND

  • You were diagnosed with type 1 diabetes less than 3 months ago.

If you are not eligible for this study, there may be other studies for people newly diagnosed with type 1 diabetes.

Other Information

Read article published by JDRF

JDRF – New Onset Type 1 Diabetes Study

Closed to Recruitment